Rafferty Asset Management
VIR icon

Rafferty Asset Management’s Vir Biotechnology VIR Stock Holding History

Rafferty Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Buy
137,469
+3,056
+2% +$29.1K ﹤0.01% 727
2026
Q1 		$1.2M Buy
134,413
+647
+0.5% +$5.16K ﹤0.01% 722
2025
Q4 		$807K Buy
133,766
+18,981
+17% +$113K ﹤0.01% 833
2025
Q3 		$655K Sell
114,785
-17,236
-13% -$88.1K ﹤0.01% 862
2025
Q2 		$665K Sell
132,021
-39,112
-23% -$210K ﹤0.01% 831
2025
Q1 		$1.11M Buy
171,133
+50,410
+42% +$448K ﹤0.01% 719
2024
Q4 		$886K Sell
120,723
-53,129
-31% -$419K ﹤0.01% 817
2024
Q3 		$1.3M Buy
173,852
+28,005
+19% +$243K ﹤0.01% 739
2024
Q2 		$1.3M Sell
145,847
-293,476
-67% -$2.81M ﹤0.01% 757
2024
Q1 		$4.45M Buy
439,323
+40,353
+10% +$411K 0.02% 498
2023
Q4 		$4.01M Sell
398,970
-126,347
-24% -$1.15M 0.02% 496
2023
Q3 		$4.92M Buy
525,317
+213,477
+68% +$3.04M 0.03% 389
2023
Q2 		$7.65M Buy
311,840
+10,994
+4% +$276K 0.04% 300
2023
Q1 		$7M Sell
300,846
-7,581
-2% -$194K 0.05% 294
2022
Q4 		$7.81M Sell
308,427
-1,150
-0.4% -$28.2K 0.07% 270
2022
Q3 		$5.97M Buy
309,577
+144,410
+87% +$3.67M 0.06% 294
2022
Q2 		$4.21M Sell
165,167
-79,670
-33% -$1.86M 0.04% 310
2022
Q1 		$6.3M Buy
244,837
+123,896
+102% +$3.67M 0.04% 314
2021
Q4 		$5.06M Buy
120,941
+60,674
+101% +$2.38M 0.03% 387
2021
Q3 		$2.62M Buy
60,267
+2,973
+5% +$129K 0.02% 549
2021
Q2 		$2.71M Sell
57,294
-150,966
-72% -$6.86M 0.02% 545
2021
Q1 		$10.7M Buy
208,260
+158,277
+317% +$8.53M 0.07% 160
2020
Q4 		$1.34M Buy
+49,983
New +$1.62M 0.01% 458

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Rafferty Asset Management's VIR Position: Q2 2026 in Review

Rafferty Asset Management increased its Vir Biotechnology (VIR) stake by 2.3% in Q2 2026, buying an estimated $29.1K and bringing the position to 137,469 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #727.

Rafferty Asset Management first reported a position in VIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $10.7M in Q1 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Rafferty Asset Management held 137,469 shares of Vir Biotechnology worth $1.4M as of Q2 2026.
  • Rafferty Asset Management bought 3,056 Vir Biotechnology shares in Q2 2026, an estimated $29.1K.
  • Vir Biotechnology made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #727 holding.
  • Rafferty Asset Management first reported a position in Vir Biotechnology in Q4 2020 and has held it in 23 quarters since.
  • Rafferty Asset Management's Vir Biotechnology position peaked at $10.7M in Q1 2021.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.